This systematic review and meta-analysis demonstrate that primary G-CSF prophylaxis with pegfilgrastim, filgrastim and lenograstim is effective in reducing the risk of FN in adults undergoing chemotherapy for solid tumours or lymphoma. Here, CSF3 is linked to lymphoma.